4D Molecular Therapeutics opened lower at $12.59, compared with its previous close of $12.99. In the last trading session, the stock traded between $12.04 and $12.86. It showed a downward intraday trend.
An investment of $100 made 5 years ago in 4D Molecular Therapeutics is now worth
$ 48.87
Resulting in a loss of
$ 51.13 (51.13%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.88 (-6.81%)
Day High
$12.86
Day Low
$12.04
Day Open
$12.59
Prev Close
$12.99
Volume
7,02,153
1W Return
-1.33%
1M Return
-6.86%
3M Return
5.50%
6M Return
12.20%
1Y Return
12.09%
Market Cap ($ Mn)
669
PE Ratio
-
PB Ratio
1.99
PEG Ratio
-
ROE
-30.78%
ROCE
-33.69%
EPS (TTM)
$-1.32
1 Week
-1.33%
1 Month
-6.86%
3 Months
5.50%
6 Months
12.20%
9 Months
30.88%
4D Molecular Therapeutics grants 260,000 stock options to new hires
Granted 260,000 stock options and 157,600 RSUs to 13 new non-executive employees. Stock options carry an exercise price of $12.36, equal to the closing price on October 13, 2026. Awards issued under the 2025 Employment Inducement Award Plan per Nasdaq Rule 5635(c)(4). Lead candidate 4D-150 is in Phase 3 development for wet age-related macular degeneration.
27 days ago4DMT grants 96,000 RSUs to seven new employees
4D Molecular Therapeutics granted 96,000 RSUs to seven new non-executive employees. Awards were approved by the compensation committee on September 8, 2026. Grants issued under the 2025 Employment Inducement Award Plan per Nasdaq Rule 5635(c)(4). Lead candidate 4D-150 remains in Phase 3 development for wet age-related macular degeneration.
2mo ago4DMT grants 35,200 RSUs to five new non-executive employees
4D Molecular Therapeutics awarded 35,200 RSUs to five new non-executive employees on August 11, 2026, under its employment inducement plan. The grants, approved by the compensation committee, align with Nasdaq rules for attracting new talent. The company continues to advance its lead candidates 4D-150 and 4D-710.
3mo ago4DMT reports positive 2-year data from PRISM Phase 2b trial
4D Molecular Therapeutics announced positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) population. The data demonstrated maintained visual acuity and anatomic control with a consistent and durable reduction in treatment burden following a single intravitreal dose. 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings through 2 years.
3mo agoHC Wainwright reiterates Buy on 4D Molecular Therapeutics
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating for 4D Molecular Therapeutics, maintaining a price target of $36. The stock trades on NASDAQ under the symbol FDMT.
3mo ago4D Molecular Therapeutics grants 37,900 RSUs to new employees
4D Molecular Therapeutics granted 37,900 Restricted Stock Units to six new non-executive employees on July 14, 2026, under its 2025 Employment Inducement Award Plan. The grants were made pursuant to Rule 5635(c)(4) of The Nasdaq Global Market. The Company is a late-stage biotechnology firm focused on therapeutics for retinal diseases and cystic fibrosis.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in 4D Molecular Therapeutics is now worth
$ 48.87
Resulting in a loss of
$ 51.13 (51.13%)
Note: Past profits do not guarantee future returns.
